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Regulators and risk managers in general need to decide whether an allergenic food or ingredient is of
such public health importance that it needs to be actively managed. There is therefore a need to scale the
relative allergenicity of foods and ingredients according to the hazards they pose. Objective criteria in-
crease transparency and trust in this decision-making process and its conclusions. This paper proposes a
framework that allows categorisation and prioritisation of allergenic foods according to their public
health importance. The challenge is to ﬁnd a basis on which the allergenicity of foods can best be
described and a method to combine the relevant measures of allergenicity into a scoring system that
prioritises allergenic foods on the basis of their public health relevance. The framework is designed in
accordance with the generic risk analysis principles used in food safety and can be used by regulators to
decide whether or not a speciﬁc allergenic food or ingredient is of sufﬁcient public health importance
that it warrants regulation (i.e. mandatory labelling) when used in the production of food products.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Food allergies can result in life-threatening reactions and
diminish quality of life. With a prevalence of up to 3% in Europe
(Muraro et al., 2014; Nwaru et al., 2014), food allergy is among the
most prevalent disorders in the western world. In the past decades
the prevalence of food allergies appears to have increased in several
regions throughout the world. Although more than 170 foods have
been identiﬁed as being potentially allergenic (Heﬂe et al., 1996), a
minority of these foods cause the majority of allergic reactions.
Some commonly allergenic foods (e.g. milk and eggs) are ubiqui-
tously important on a worldwide basis while other foods most
commonly causing allergic reactions vary between geographic re-
gions (Burks et al., 2012). Food allergen labelling legislation
currently varies across the globe (Gendel, 2012) but is usually based
on the Codex list (Codex Alimentarius, 1999). However, presenting
labels which meet consumer needs as well as regulatory re-
quirements has been problematic (Cornelisse-Vermaat et al., 2008),
particularly in relation to precautionary labelling to indicate
possible unintended allergen presence in food products. Food
allergen labelling legislation has not always been based on scien-
tiﬁc evidence.
There is a need to scale the relative allergenicity of foods and
proteins and the hazards or risks arising from this allergenicity. This
includes proteins which pose a known risk to the public and novel
proteins arising from biotechnology, modiﬁed species or new food
sources. Prioritisation according to the public health impact of
allergenic foods ensures that scarce resources are allocated in such
a way that they address those allergens that matter most from a
public health point of view. Both regulators and risk managers in
general need to decide whether a food allergen is of such public
health importance that it must be actively managed. Objective
criteria would improve transparency and trust in the decision-
making process and its conclusions.
For the last six years, the ILSI Europe Food Allergy Task Force has
developed methods to identify and assess the evidence (schemat-
ically represented in Fig. 1). The ﬁrst peer-reviewed publication
focused on scientiﬁc criteria for identifying allergenic foods of
public health importance (Bj€orksten et al., 2008). A subsequent
publication evaluated their application and further reﬁned them by
incorporating an assessment of the strength of available scientiﬁc
evidence (Van Bilsen et al., 2011). An assessment of the quality of
evidence of the scientiﬁc literature available as well as an attempt
to test the applicability, completeness and ease of use of theapproach suggested in the previous papers was later conducted
during a workshop with key stakeholders in September 2010
(Chung et al., 2012).
This paper proposes a framework that would allow catego-
risation and prioritisation of allergenic foods according to their
public health importance. The challenge we address is to propose
measurements on the basis of which the allergenicity of foods can
best be described and a method to combine the relevant allerge-
nicity measurements into an approach to categorise and prioritise
their public health relevance. Once the relevant measurements
have been deﬁned, with a clear method of grading them individ-
ually, this grading can be used as a basis for ranking allergenic foods
relative to each other as threats to public health. Risk managers can
then decide on a possible categorisation and prioritisation for risk
management purposes. The framework, based on a hazard scaling
approach that ﬁts in the risk analysis cycles for food allergens, can
be used to decide on labelling advice.
In Section 2, the application of the generic risk analysis cycle to
allergenic foods is addressed on the basis of which the most
appropriate parameters for scaling allergenicity are selected. Sec-
tion 3 addresses how these parameters (prevalence and potency)
can be used to categorise and prioritise allergenic foods according
to their public health relevance and gives examples for such cate-
gorisation and prioritisation as a demonstration of principle. The
establishment of actual prevalence and potency data to be used for
the various allergenic foods and therewith the actual application of
the categorisation and prioritisation approach is beyond the scope
of this paper and should be subject of future projects. In Section 4
the use of the hazard scaling in categorisation and prioritisation
for risk management purposes in the risk analyses process is
addressed.
2. The risk analysis cycle applied to food allergy and
parameters for hazard scaling
The ultimate purpose of the frameworkwe propose is to provide
an approach to decide whether or not a speciﬁc food or ingredient
is of sufﬁcient public health importance due to allergenicity that it
warrants regulation (i.e. mandatory labelling) when used in the
production of food products. This decision will determine which of
more than 170 allergenic foods should be included in the allergenic
ingredient labelling requirement for foods to enable allergic con-
sumers to avoid these ingredients.
When introducing a hazard categorisation and risk
Fig. 1. The journey of the ILSI Europe Food Allergy task force in respect of prioritising allergenic foods according to public health importance.
G. Houben et al. / Food and Chemical Toxicology 89 (2016) 8e1810management approach, it is important to adhere, as far as possible,
to existing well established and accepted frameworks. Approaches
to food safety have become internationally harmonised during the
past decades and generally follow the principles of the risk analysis
cycle as published, amongst others, by WHO IPCS (International
Programme on Chemical Safety et al., 2004). The chart in Fig. 2
summarises how the classical risk analysis cycle might be applied
to the topic of food allergens.
For allergenic foods, two risk analysis cycles can be distin-
guished. The ﬁrst is the risk analysis for sensitisation to the aller-
genic food. This is not the principal subject of the prioritisation tool
presented in this paper. The outcomes from the risk analysis for the
sensitisation phase (risk as represented by the prevalence of allergyFig. 2. The generic risk analysis cycle (toand the sensitivity of the allergic population for developing allergic
reactions upon exposure) are the appropriate “hazard” input for the
risk analysis of the elicitation phase, which is the subject of the
prioritisation tool presented in this paper. The sensitising potency
of an allergenic food together with the degree and pattern of
exposure and various other factors determine the prevalence of
sensitisation and subsequent allergies in the population and the
sensitivity of the allergic individuals, which are developed during
the sensitisation phase. The prevalence of food allergies in the
population and the sensitivity of the allergic individuals/the po-
tency of the allergenic food for elicitation of reactions, together
with the degree and pattern of exposure to the allergenic food and
various other factors, determine the frequency and severity ofp) applied to food allergy (bottom).
G. Houben et al. / Food and Chemical Toxicology 89 (2016) 8e18 11allergic reactions in allergic individuals, which are developed dur-
ing the elicitation phase.
Fig. 2 shows that exposure of susceptible individuals to an
allergen in the elicitation phase is not an independent determinant.
In the elicitation phase, exposure depends on risk management
actions, including labelling, that may inﬂuence more than anything
else, the level of exposure in the allergic subpopulation and thus
the frequency and severity of allergic reactions in that population.
When there is a low frequency of severe reactions to a certain food,
this may indicate good risk management and does not by itself
imply that the food should not be a regulated allergen for labelling.
Our tool aims at classifying the inherent allergenic properties,
regardless of whether they are already well managed in terms of
exposure potential, or not. The chart in Fig. 3 explains schematically
how exposure to allergens is inﬂuenced by the risk management
actions already in place and why an assessment of the inherent
properties of allergens should be independent of the level of
exposure that determines the frequency of occurrence of (severe)
reactions.
Similar to the exposure element, the severity of allergic re-
actions as observed in the population is not an independent
determinant in an allergen hazard ranking exercise. The severity of
allergic reactions occurring as a consequence of exposure is inﬂu-
enced by the dose ingested and the potency of the allergen/the
sensitivity of the allergic consumer to that allergen. Severity is a
component of risk, as risk is deﬁned as the function of both the
likelihood and the severity of an adverse event. Severity of allergic
reactions in the population therefore should be taken into consid-
eration in the risk management decision making phase, but should
not be part of the allergen speciﬁc hazard assessment.
Based upon the above reasoning, the expert group concluded
that the two independent determinants most appropriate for
expressing the potential of allergens to elicit allergic reactions on a
population level, are the prevalence of the allergy and the potency
of the allergen; the latter being reﬂected in the distribution of
sensitivity of the allergic population to the allergen under assess-
ment. Prevalence and potency can be deﬁned as independent and
measurable dimensions: prevalence from the allergic proportion of
the population and potency from population threshold dose-
distribution curves. The development of a hazard scalingFig. 3. The inﬂuence of risk managemapproach therefore can best be based on these measurements that
represent the hazard information in the risk analysis cycle for the
elicitation phase.
The parameters and approach for scaling allergenic foods ac-
cording to their public health importance as proposed in this paper
is based on a scaling approach under development by TNO, The
Netherlands, in the framework of a programme aimed at devel-
oping an approach for predicting and scaling the relative allerge-
nicity of novel or modiﬁed food proteins (Houben et al., in
preparation). Although the latter approach is mainly focussed on
the sensitisation phase and the approach proposed in this paper on
the elicitation phase, the two approaches are linked because the
outcomes from the risk analysis for the sensitisation phase (i.e. the
risk as deﬁned as the chance of and severity of an adverse effect, in
the case of sensitisation represented by the prevalence of allergy
and sensitivity of the allergic subjects) are the appropriate hazard
input for the risk analysis of the elicitation phase (see also Fig. 2).
3. Scaling of allergenic foods according to public health
relevance
3.1. Evaluation parameters for prevalence and potency
The prevalence of allergy to a speciﬁc food is a rather straight
forward parameter.We can deﬁne this prevalence as the proportion
of the population that is allergic to that speciﬁc food. Though
simple by deﬁnition and as such in principle requiring little dis-
cussion for use in the hazard scaling approach that we propose, the
prevalence of allergies to various foods is not easy to establish and
subject to many methodological issues. As this paper aims to pre-
sent a hazard prioritisation approach and not a methodological
discussion on epidemiological issues in establishing the prevalence
of food allergies, these issues will not be discussed further and
prevalence data used in this paper are to be considered for the
purpose of illustrating the hazard scaling approach rather than as
actual estimates of prevalence. For a recent overview of food allergy
prevalence data, we refer to a report for EFSA (University of
Portsmouth (2013)) and the EAACI Food Allergy and Anaphylaxis
Guidelines.
The most appropriate expression of potency for use in hazardent actions on exposure and risk.
Fig. 4. a) Two hypothetical threshold dose-distribution curves with the same ED50 but
different slopes; b) Two hypothetical threshold dose-distribution curves with the same
ED10 but different ED50.
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deﬁne. There is not just a single potential value for the potency of
an allergen for effect elicitation. The potency of an allergen is
typically assessed in a clinical setting by means of food challenge
studies in which allergic individuals are exposed to increasing
amounts of the food to which they are allergic. For each allergic
individual participating in such a study, the individual no observed
adverse effect level (NOAEL) and lowest observed adverse effect
level (LOAEL) are obtained. In theory, no and lowest observed effect
levels can be assessed for various (types of) reactions separately, for
instance for oral, GI-tract or dermal reactions or the more severe
reactions involving the respiratory and/or cardio-vascular system.
Some stakeholders may prefer to base a hazard categorisation on
the intrinsic potency or capability of allergens to induce severe or
more dangerous effects. Such information however is not available
as challenge studies generally are terminated prior to reaching
doses that induce severe reactions. As explained in the previous
section, severity of allergic reactions in daily life is not an inde-
pendent determinant in an allergen hazard ranking exercise but is a
risk term and as such inﬂuenced by the level of exposure. The
Expert Group therefore proposes to use, as a basis to estimate po-
tency, the distribution of the minimum doses eliciting any type of
objective allergic reaction as a basis for hazard scaling, as this will
automatically also cover more severe or dangerous types of allergic
reactions. The dose eliciting an allergic reaction in 50% or the
allergic population (ED50) is proposed as the measure of potency
for scaling and comparison between various allergenic foods.
Within the food allergic population there can be substantial
variability in sensitivity between individuals, (Taylor et al., 2009;
Wensing et al., 2002a,b). A threshold dose-distribution for the
allergic population of a speciﬁc food can be constructed describing
the cumulative proportion of the population reacting to an
increasing dose of an allergenic food, the latter usually expressed
on a milligram (mg)-protein scale. For the purpose of scaling
allergenic foods with respect to potency, we need to derive a useful
summary statistic from this threshold dose-distribution that has
the following properties: 1) It should reﬂect potency, i.e., be a valid
measure. 2) It should be easy to interpret. 3) It should capture the
variability between foods and distinguish sufﬁciently between
allergenic foods in order to scale them. Robustness of the estimate
is a concern, since the number of observations and quality of
challenge studies varies considerably between food products (for
example, for peanut many more individuals have participated in
challenge studies than for shrimp).
An obvious choice as a summarizing statistic would be the
median of the threshold distribution, often denoted as the ED50,
the dose at which 50% of the allergic populationwill show objective
symptoms. It ﬁts the mentioned criteria: 1) The ED50 captures the
location of the threshold distribution on the mg-protein scale and
as such is a valid measure of potency. Themedian is also known as a
robust statistic that is not as sensitive to outliers as, for example,
the mean. 2) The ED50 is easy to interpret. 3) In Section 3.3, several
examples of scaling of known allergenic foods are given and from
these examples it appears that the ED50 does vary between aller-
genic foods and distinguishes allergenic foods with different po-
tencies sufﬁciently.
An important question is how to deal with two allergenic foods
having the same ED50 but differing in their ED10, ED05, etc. Sta-
tistically speaking, should the variance of the threshold distribution
be taken into account in the scaling approach? An example of this is
shown in Fig. 4 a showing two imaginary threshold curves with the
same ED50 (at the intersection with the vertical line) but different
values for the ED10 and ED90, in other words, the cumulative
probability curves have different slopes. A practical and statistical
argument for not taking account of this variance in the thresholddistribution is that it is difﬁcult to obtain comparable levels of ac-
curacy of estimation for different allergens, due to substantial
variability in available sample sizes for the allergenic products. This
makes comparisons of the ED10 or ED05 less robust. A methodo-
logical reason for focusing solely on the ED50 and ignoring the
ED10 and ED90 is that the purpose of the prioritization is to protect
the whole allergic population, and not speciﬁcally the most sensi-
tive part of the allergic population. For allergenic foods that
demonstrate a ﬂatter slope, the allergic population is somewhat
more sensitive below the ED50 in comparison with an allergenic
food with a steep slope. However, above the ED50, the allergic
population is somewhat less sensitive in comparison with an
allergenic foodwith a steep slope. Fig. 4 b gives another example. In
this case we consider two hypothetical threshold dose curves with
the same ED10 value, but different ED50 values, again due to
different slopes. The curvewith the steepest slope obviously is from
the most potent allergen in terms of effect elicitation, which is
clearly reﬂected by a lower ED50 value, while the ED10 values
would not provide this information.
The ED50 thus seems an appropriate parameter for scaling po-
tency and other options are less robust and/or give no additional
information. The expert group therefore decided to use the ED50
for objective effects as the parameter for scaling the potency of
allergenic foods.
3.2. Proposed scaling approach: combining prevalence and potency
information
When considering how to combine the two chosen parameters,
prevalence and potency, the expert group considered capturing the
G. Houben et al. / Food and Chemical Toxicology 89 (2016) 8e18 13“level of allergenicity” into one single value and scale. However,
there are no ﬁrst-principles from which to derive a single scale or
score. Any derivation of a single representative value would imply a
relative weighting of each of the two scores for prevalence and
potency. In the absence of criteria on which to base such a
weighting, the Expert Group considered it best not to combine the
parameters but to express them graphically, keeping the detail of
the two independent dimensions. In paragraph 3.3, various exam-
ples of scaling of allergenic foods are given as a proof of concept
illustration of the hazard scaling approach. This graphical repre-
sentation of the hazard characteristics, as modelled by their prev-
alence and potency, can then serve as the basis for categorisation
and/or prioritisation. The resulting position of individual foods in
the 2-dimensional plot relative to each other can be used by risk
managers for risk management decision making. Various options of
how to use the information in risk management exist, for instance
by drawing borders of categorisation between allergenic foods of
low or high public health relevance. In Section 4, the use of the
hazard scaling in categorisation and prioritisation for risk man-
agement purposes in allergen risk analyses is addressed.
3.3. Examples of scaling as a proof of concept illustration of the
hazard scaling approach
In this paragraph, prevalence and potency data for several
allergenic foods are used to present some examples as a proof of
concept illustration of the hazard scaling approach. Data on aller-
genic foods covering a wide range of estimates of prevalence and
potency were selected to obtain examples that illustrate how dif-
ferences in allergenicity (prevalence and potency) and data avail-
ability and quality can be captured in a graphical scaling. The
selection of allergenic foods and studies or data points therefore
was based on capturing:
 differences in prevalence and potency.
 differences in amount of available data points.
 differences in data quality.
In view of the selective data choices speciﬁcally aimed at
capturing such differences, prevalence and potency data used in
this paragraph are not to be considered as actual estimates of
prevalence or potencies of the allergenic foods selected but are only
meant for illustrative purposes.
For prevalence, several studies from a report for EFSA were
selected. For potency, ED50 values derived from the TNO-FARRP
Threshold Data Base that was also used for the elaboration of
Reference Doses in the framework of the development of the VITAL
2.0 approach (Allen et al., 2009; Taylor et al., 2014) were used. In
Table 1, the allergenic foods and data points selected for proof of
concept illustration are listed. Fig. 5 gives a proof of concept illus-
tration of scaling of allergenic foods according to their public health
relevance in effect elicitation based on these allergenic foods and
data points selected.
4. Prioritisation of allergenic foods according to public
health relevance in the risk analysis process
4.1. Hazard categorisation as a basis for risk management decision
making
The scaling approach proposed and illustrated as a proof of
concept in section 3 can be used for risk management decision
making. The ultimate choice of how to use the hazard information
in risk management is up to regulators. The approach could be a
basis for deciding whether or not to include certain allergenicfoods or ingredients in the labelling legislation. This could be done
by drawing a boundary in a graph such as in Fig. 5 between the
prevalence and potency combinations that would represent
allergenic foods of high and low hazard. Once ﬁlled with
consensus data on prevalence and potency for the allergenic foods
or ingredients, this could be the basis for allocation of these foods
and ingredients to a category of allergenic foods of either low or
high public health importance. The approach would also allow the
amount and quality of data on prevalence and potency to be taken
into consideration and decisions could be postponed if data were
not considered sufﬁcient for decision making, or made on a con-
ditional basis if a more precautionary stance is deemed appro-
priate. Lack of sufﬁcient appropriate data might be used to
inﬂuence research priorities. Based upon the position in the two
dimensional chart, and the amount and quality of available data
that underpin the prevalence and potency assessment, one can
divide the outcome of the assessment of the allergenic foods into
different decision categories, purely based on the hazard
assessment:
1. Allergens of high public health relevance, based on their prev-
alence/potency position, stemming from a strong set of data ->
advice to label.
2. Allergens of low public health relevance, based on their preva-
lence/potency position, stemming from a strong set of data ->
advice not to label.
3. Allergens for which only a limited data set and/or data of low
quality are available -> allergens put “on hold” from a hazard
assessment point of view but subcategorised according to high
or low priority research needs depending on the potential public
health relevance suggested by data available. In general, no
change in management regime would be expected until addi-
tional data of sufﬁcient quality would indicate another decision,
although other legitimate factors could drive a deviation from
this principle.
This would result in 4 distinct hazard characterisation categories
as illustrated in Table 2.
With the data generated by the hazard classiﬁcation approach
proposed in Table 2, risk managers can make risk management
decisions and/or perform risk management interventions. In the
case of large amounts and good quality data supporting the allo-
cation of allergens to either high or low health relevance, the risk
management decision to be taken may be quite straightforward.
For allergens having ended up in the categories “on hold”, addi-
tional research may be needed.
We illustrate the approach for cases with limited data avail-
ability by means of three unregulated allergens that were included
in the examples in Table 1 and Fig. 5: kiwi, rice and apple. The
location of a set of well-known allergenic foods on the allergenicity
scale gives a frame of reference for assessing new allergens. The
prevalence and potency data used are only meant for demonstra-
tion of principle and not as actual prevalence and potency esti-
mates. However, if the data used in Table 1 and Fig. 5 were the
actual established consensus data for these allergens, the kiwi, rice
and apple cases could be assessed as outlined in the case de-
scriptions below.
For illustrating the assessment in the case studies, a cut off for
allocating an allergenic food to the category of allergenic foods of
either low or high public health importance is needed as a refer-
ence. For this illustration, an established cut off as illustrated in
Fig. 6 is assumed. The actual establishment of this cut off as well as
how to deal with allergens for which a 95% Conﬁdence Interval (CI)
crosses the established boundary (as is the case for ﬁsh and kiwi in
the example of Fig. 6), is a risk management responsibility.
Table 1
Allergenic foods and data points selected for proof of concept illustration.
Allergenic
food
Potency ED50, in mg protein
(95% CI)
Data level of
evidence (*)
#Threshold data
points
Prevalence %
(95% CI)
Data level of
evidence (*)
Remarks
Egg 53 (35e81) 1 180 0.1 (0e0.7) 1 (Osterballe et al., 2005) n ¼ 936, age > 22,
DBPCFC
Fish 256 (88e738) 1 19 0.2 (0e0.9) 1 (Osterballe et al., 2005) n ¼ 936, age > 22,
DBPCFC
Sesame 132 (52e336) 1 21 2.2 (1.7e2.7) 2 (Zuberbier et al., 2004)
Mustard 14 (7e30) 1 33 3 (2.1e4.3) 4 (Touraine et al., 2002)
Prevalence is self-reported, France only
Milk 68 (51e90) 1 351 0.3 (0.1e1.0) 1 (Osterballe et al., 2005) n ¼ 936, age > 22,
DBPCFC
Peanut 78 (66e92) 1 751 0.4 (0.1e1.2) 1 (Osterballe et al., 2005) n ¼ 936, age > 22,
DBPCFC
Celery 65 (30e140) 1 39 3.5 (2.9e4.2) 2/3 (Zuberbier et al., 2004) (SPT)
Apple 84 (84e140 gr) 2e4 2 2.2 (1.8e2.8) 2/3 (Zuberbier et al., 2004) (SPT)
Kiwi 29 (6e132) 1 14 0.8 (0.5e1.3) 4 (Rance et al., 2005)
Self-reported, n ¼ 2716
Rice 318 (170e594) 1 13 0.13 (0e1) 3 (Eriksson et al., 2004)
(*) (Van Bilsen et al., 2011).
Fig. 5. Proof of concept illustration of scaling of allergenic foods according to their public health relevance in effect elicitation (Evidence ¼ quality level of evidence: 1 ¼ highest,
4 ¼ lowest quality); (Van Bilsen et al., 2011). For details regarding data, see Table 1.
Table 2
Hazard characterisation categories for allergenic foods and ingredients based on assessed public health relevance and data quality and availability.
Quality and availability of evidence
Public Health Importance (based on potency and prevalence information) High Low
High High public health importance Potentially high public health importance
Well established “On hold”; research needed
Labelling required High priority research
Low Low public health importance Likely low public health importance
Well established “On hold”; research needed
No labelling required Low priority research
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The potency data for apple was from two patients who under-
went a food challenge but of a lower data quality level than aDBPCFC. The resulting estimate for the potency of apple was 30 g of
apple, with a range of 30e50 g, corresponding to 84e140 mg
protein. Prevalence data gave an estimate of the prevalence of apple
Fig. 6. Illustration of a possible risk management choice for cut-off between allergenic foods of low and high public health importance. For details regarding scaling and data
selection, see paragraph 3.3, Table 1 and Fig. 5.
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quality as the best evidence was based on self-reports and the skin
prick test. In conclusion, the quality of evidence for apple can be
considered low for both potency and prevalence, but the reported
potency and suggested prevalence are comparable to other regu-
lated allergenic foods (see Fig. 5 and Table 1). Therefore, the derived
conclusion may be that apple is likely to be an allergenic food of
high public health importance, that research is needed and that this
is of high priority. It should be noted that apple allergy may be
different from other allergies, for instance because of the well-
known instability of the major allergenic protein. This may pose
another perspective with respect to the risks due to cross
contamination of food products with apple proteins. Such aspect
may be taken into consideration in the ultimate risk management
decision making.
4.1.2. Case 2 e kiwi
The potency estimate for kiwi was based on DBPCFC data (14
patients) and thus of high data quality. The ED50 was estimated at
29 mg protein (95CI 6-132), which indicates a relatively highly
potent allergenic food, being more potent than peanut or milk and
only less potent than mustard. The prevalence was estimated at
0.8% (0.5e1.3), but based on self-reports and thus of low data
quality. Therefore, we conclude in this case that kiwi is likely to be
an allergenic food of high public health importance, mainly because
of the estimated high potency, and more research is needed with a
relatively high priority.
4.1.3. Case 3 e rice
The potency estimate for rice was based on DBPCFC data (13
patients) and thus of high data quality. The ED50 was estimated at
318 mg protein (95CI 170-594), which indicates a low to moder-
ately potent allergen, comparable to, for instance, ﬁsh. Prevalence
data provided an estimate for the prevalence of rice allergy in in-
dividuals allergic to other foods. The resulting estimate for the
prevalence of rice allergy was only 0.13%. A conﬁdence interval isnot available, since the original estimate did not provide this.
Therefore, we conclude that rice, given its low tomoderate potency
and its low estimated prevalence, is likely to be of low public health
importance. More research is needed but this is of low priority.
4.2. Other factors inﬂuencing risk management decision making
Risk management decisions can be based solely on hazard in-
formation, but as illustrated in Fig. 2, risk management decisions
may also take into consideration the frequency and/or level of
exposure and/or the consequential frequency and/or severity of
effects in the population (i.e. the risk) and/or other legitimate fac-
tors. Other legitimate factors often are associated with the impact
of the risk management options. Several of these possible factors
are brieﬂy discussed below. In principle, some of these factors could
be taken into consideration in the hazard categorization method
proposed in this paper, provided that relevant prevalence and po-
tency data for the processed food ingredients are available. An
example is the potential loss of allergenicity of proteins or loss of
allergenic proteins during processing. However, as such consider-
ations may be process or processed food product speciﬁc and may
not be generic for the original allergenic food, it is preferable to
separate the use of such information in the risk management de-
cision making from the hazard categorization of the original aller-
genic food. For example, loss of allergenic proteins during the
production of a highly reﬁned vegetable oil might be a reason for
exempting such oil from labeling requirement (risk management
decision) but does not make the original allergenic food (e.g. pea-
nut) of low public health importance (hazard categorization of the
original allergenic food) requiring no or low risk management
priority.
4.2.1. Avoidability, visibility and ascertainability
Many aspects of an allergic food may relate to its visibility,
including its suitability for being an ingredient in prepared foods
and its allergenic stability when prepared for consumption by
G. Houben et al. / Food and Chemical Toxicology 89 (2016) 8e1816cooking and/or heating. All other things being equal, readily visible
allergenic foods are less likely to require control than allergenic
foods which are easily and commonly “hidden” in prepared foods.
4.2.2. Reputation and image
Foods may become fashionable or unfashionable because of
numerous actual or perceived beneﬁts or drawbacks. While this
may affect the prevalence of consumption and frequency of allergic
reactions, they may also affect societal demand for control. Certain
allergenic foods may also have a “bad reputation” amongst patients
and the general public as being a relatively frequent cause of
particularly severe or fatal reactions, such as peanut (see below).
4.2.3. Effects on quality of life
Measurements of health related quality of life (HRQL) in food
allergy are relatively new. Among the ﬁrst instruments developed
for this purpose were those of the EuroPrevall project. While these
instruments have proven valid and useful for measuring HRQL in
different food allergic populations and settings, only a few studies
have included analyses of differences in the degree of HRQL
impairment in patients allergic to different foods.
DunnGalvin et al. (2008) found that peanut allergy was associ-
ated with poorer HRQL than other forms of food allergy. This could
not be conﬁrmed in a subsequent study where most children were
peanut allergic, so that a clear conclusion could not be reached
(Wassenberg et al., 2012). In a recent analysis of data from the
EuroPrevall study, multiple linear regression analyses were per-
formed to develop models for predicting HRQL in children and
adults from different European countries (Saleh-Langenberg et al.,
2015). These results show that wheat and ﬁsh allergies were
associated with poor quality of life in adults, whereas peanut and
soy allergies were associated with poor quality of life in children.
While there is currently little information of health related
quality of life (HRQL) differences between allergenic foods, the
content of HRQL instruments show important domains of patient
experience which are likely to make certain allergenic foods more
important to allergic individuals than others. These include foods
that are relatively important adjunct to social interactions, partic-
ularly those where there is some inherent uncertainty about the
stringency of avoidance during preparation. Allergenic foods which
are served at parties, in restaurants or at other social gatherings
might thus be more likely to require control than allergenic foods
where this is of less relevance.
4.3. Initiation of a risk analysis process and risk management
decision making
A risk analysis process leading to risk management decision
making generally will not be executed spontaneously. Changing
societal or legislative situations, routine updates or re-assessments
or identiﬁed or suspected changing or emerging risks may trigger
the start of such a process. As the approach using potency and
prevalence as the discriminating factors for categorizing foods or
ingredients according to the public health relevance of allergenicity
is going to generate a snapshot at a given point in time, it is going to
be worth adopting an approach capable of keeping track of the
continued relevance of an established ranking over time, and able
to identify when an update of the analysis is required. Aside from
new scientiﬁc information, several factors may necessitate the
reconsideration of a ranking of public health relevance. The expert
group considered these factors, and clustered them under the term
“horizon scanning”, to express the idea that an ongoing monitoring
activity could provide an alert that an update of the public health
relevance assessment may be needed. The expert group assessed
both the scope of such horizon scanning, as well as parameters andsources of information that could be of relevance. Horizon scanning
could play a double role, at two different stages of the overall risk
analysis process of allergenic foods:
1. First of all, horizon scanning could inform the initial hazard
analysis, by scanning scientiﬁc information for relevant new
data on potency and prevalence of already previously assessed
and ranked allergenic foods. It could also scan relevant sources
of information for the occurrence of newly emerging allergens,
for the increase of incidence of allergies which were previously
deemed less common or for identifying discrepancies between
conclusions from previous assessments and new data. In this
role, horizon scanning could not only provide a trigger for
updating a hazard assessment of a previously ranked allergenic
food, but could also trigger to assess a previously unassessed,
newly emerging allergen.
2. Secondly, horizon scanning could provide input on other legit-
imate factors, which could be used by risk managers, in order to
take their decisions on which of the allergenic foods or in-
gredients might require prioritized risk management actions,
such as labelling obligation, and which foods or ingredients do
not.
Based upon these two roles of horizon scanning, the expert
group compiled a list of examples of measurements and informa-
tion sources that might be relevant for horizon scanning (see
Table 3). They remarked that, establishing the role of horizon
scanning, with the appropriate factors and scope, also renders
horizon scanning capable of capturing for instance possible
geographical differences in public health relevance of allergens.
4.4. The overall risk analysis process
As described in the previous sections, the expert group proposes
a hazard categorisation approach for prioritising allergenic foods or
ingredients according to their public health relevance, based on 2
hazard parameters, i.e. potency and prevalence, as a step in the risk
analysis cycle to be applied for binary decision making: should an
allergenic food or ingredient be subjected to obligatory labelling as
an allergenic ingredient or not. The approach can be applied to any
food or ingredient. For some foods or ingredients, sufﬁcient data of
good quality will be available for applying the hazard categorisation
approach. In such cases the food or ingredient can be categorised
either as a food with a well-established high public health impor-
tance that should be labelled when used as an ingredient or as a
food with a well-established low public health importance for
which it has been agreed that no labelling is required. For other
foods or ingredients, insufﬁcient data or data of insufﬁcient quality
may be available for categorisation. Based on the data available,
such foods or ingredients may be classiﬁed as potentially being of
high or low public health importance, indicating respectively high
or low priority research needs. No change in management regime
would be expected until additional data of sufﬁcient quality would
indicate another decision to be made. The cut-offs for allocation to
different hazard categories will need to be decided and agreed on
by risk managers. Various other legitimate factors may inﬂuence
the ultimate risk management decision making. The risk analysis
process that results in the risk management decision may be
executed as a result of various triggers and reasons that in part may
be picked up by continuous scanning for new or changing situa-
tions or information for which horizon scanning could be of help.
All risk analysis elements proposed above can be combined in an
overall framework/ﬂow chart for risk management decision mak-
ing in establishing allergenic foods or ingredients for inclusion in
the labelling requirement (Fig. 7).
Table 3
Examples of parameters and information sources that might be relevant for horizon scanning.
Source of information Type of info looked for Examples
Scientiﬁc literature New information on potency and prevalence of food allergens
Case reports, Allergen registries Increase of case reports over time, for a given food allergen Allergene Centre Charite
Information collected by industry Increase in consumer complaints linked to a certain food allergen
Adverse events reporting trends to
authorities
Increase in reported cases/complaints CAERS (Consumer adverse
event reporting system, FDA)
Trends in the reporting of incidents, related to food allergens currently not on the EU allergens
list
EU authorities and local
member states reporting
Screening systems for (changing) dietary
intake proﬁles in a given geography
National food surveys
Changes in Eurostat data on traded foods and imports
Trends reported by already existing
screening tools
Authorities screening tools on food incidents
Commercial tools
RASSF
TNO Emerging Risk
Identiﬁcation Support
The notiﬁcation of new foods to be
introduced in a certain geography
Potential concerns related to the Novel Food criteria:
 Foods and food ingredients with a new or intentionally modiﬁed primary molecular
structure;
 Foods and food ingredients consisting of/or isolated from micro-organisms, fungi or algae
 Foods and food ingredients consisting of/or isolated from plants and animals, except when
obtained by traditional propagating or breeding practices.
 Foods and food ingredients to which has been applied a production process not currently
used, where that process gives rise to signiﬁcant changes in the composition or structure
of the food or ingredient
Foods notiﬁed under the novel
foods legislation
Fig. 7. Framework/ﬂow chart for risk management decision making in establishing allergenic foods or ingredients for inclusion in the labelling requirement.
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